Overview

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Linagliptin